Literature DB >> 30979469

Association of Tumor Grade With Long-Term Survival in Patients With Hepatocellular Carcinoma After Liver Transplantation.

Jun Zhao1, J Mao2, W Li3.   

Abstract

BACKGROUND: Association of tumor grade and the prognosis of hepatocellular carcinoma (HCC) patients after liver transplantation (LT) had not been clearly illustrated. The objective of the current study was to investigate the impact of tumor grade on the long-term survival of patients with HCC receiving LT.
METHODS: Data from Surveillance, Epidemiology, and End Results Program (SEER) 18 registry for 2004-2015 was extracted for the present study. Propensity score matching was performed to eliminate possible bias. In addition, multivariable analysis was utilized to adjust for confounding factors. The primary endpoints were overall survival (OS) and disease-specific survival (DSS).
RESULTS: A total of 802 patients diagnosed with HCC receiving LT between 2004-2015 included in the SEER registry were analyzed in the study. In the multivariable adjusted cohort (OS: n = 802; DSS: n = 640), a worse prognosis was observed in OS (HR, 1.57; 95% CI, 1.13-2.19; P = .008) and DSS (HR, 2.62; 95% CI, 1.44-4.77; P = .002) for patients with moderate/poor-differentiated tumors compared to patients with well-differentiated tumors. In stratified analyses, the salutary effects of well-differentiation on OS and DSS were consistent across all examined subgroups. In the propensity-matched cohort, the univariable analysis showed that patients with moderate/poor-differentiated tumors still had worse OS (HR 1.60, 95% CI 1.12-2.28, P = .010) and DSS (HR 2.54, 95% CI 1.36-4.74, P = .003) compared to patients with well-differentiated tumors.
CONCLUSION: Tumor grade of differentiation had a statistically significant effect on the long-term prognosis of HCC after LT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30979469     DOI: 10.1016/j.transproceed.2018.12.033

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Impact of Socioeconomic Factors on Prognosis and Clinical Management in Patients with Hepatocellular Carcinoma.

Authors:  Bing-Bing Su; Bao-Huan Zhou; Dou-Sheng Bai; Jian-Jun Qian; Chi Zhang; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

2.  Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma.

Authors:  Feiqian Wang; Kazushi Numata; Masayuki Nakano; Mikiko Tanabe; Makoto Chuma; Hiromi Nihonmatsu; Akito Nozaki; Katsuaki Ogushi; Wen Luo; Litao Ruan; Masahiro Okada; Masako Otani; Yoshiaki Inayama; Shin Maeda
Journal:  Diagnostics (Basel)       Date:  2020-05-19

3.  Nomogram based on inflammation-related markers for predicting survival of patients undergoing hepatectomy for hepatocellular carcinoma.

Authors:  Tian Pu; Zi-Han Li; Dong Jiang; Jiang-Ming Chen; Qi Guo; Ming Cai; Zi-Xiang Chen; Kun Xie; Yi-Jun Zhao; Fu-Bao Liu
Journal:  World J Clin Cases       Date:  2021-12-26       Impact factor: 1.337

4.  High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis.

Authors:  Guoshun Zhang; Bin Liu; Hua Shang; Guikai Wu; Diyang Wu; Liuqing Wang; Shengnan Li; Zhiyuan Wang; Suying Wang; Juxiang Yuan
Journal:  BMC Med Genomics       Date:  2022-08-15       Impact factor: 3.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.